IMAB

I-Mab

IMAB, USA

I-Mab, a biotech company, focuses on the development of immuno-oncology agents for the treatment of cancer in the United States. The company is developing givastomig, a bispecific antibody, which is in Phase 1b clinical trial for the treatment of gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, a bispecific antibody, which is in phase 1 clinical trial for the treatment of solid tumors. It has a strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, import, use, sell, and offer to sell FE301, an interleukin-6 inhibitor. The company also has collaborations with Bristol Myers Squibb for the development of givastomig; ABL Bio, Inc. for the development of givastomig and ragistomig; and TJ Bio for the development of uliledlimab. I-Mab was founded in 2014 and is headquartered in Rockville, Maryland.

https://www.i-mabbiopharma.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
IMAB
stock
IMAB

Will IMAB stock attract more institutional investors - July 2025 Weekly Recap & Real-Time Market Sentiment Reports moha.gov.vn

Read more →
IMAB
stock
IMAB

NovaBridge Biosciences Pursues Hong Kong Listing Amid Strategic Shift MSN

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-06-30)

Rating:

STRONG BUY

Target Price:

$8.6

Analyst Picks

Strong Buy

3

Buy

2

Hold

0

Sell

0

Strong Sell

0

Finn Analysis

(Last Updated 2025-06-30)

Health Score

Price to Book Ratio (P/B)

-

Low

1.59

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-2.80 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-2.66 %

Low ≤ 2%

High ≥ 10%

Debt to Equity

-

Very High

0.05

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 13.08% of the total shares of I-Mab

1.

Hillhouse Capital Advisors, Ltd.

(7.3237%)

since

2025/06/30

2.

Candriam Luxembourg S.C.A.

(1.3869%)

since

2025/06/30

3.

Belfius Equities Cure C Cap

(1.3869%)

since

2025/08/31

4.

SG Americas Securities, LLC

(1.0732%)

since

2025/06/30

5.

Two Sigma Advisers, LLC

(0.2564%)

since

2025/06/30

6.

UBS Group AG

(0.2264%)

since

2025/06/30

7.

Aberdeen Group PLC

(0.1671%)

since

2025/06/30

8.

BNP Paribas Arbitrage, SA

(0.1499%)

since

2025/06/30

9.

Two Sigma Investments LLC

(0.1387%)

since

2025/06/30

10.

Ariose Capital Management Ltd

(0.1181%)

since

2025/06/30

11.

Alberta Investment Management Corp

(0.0915%)

since

2025/06/30

12.

Renaissance Technologies Corp

(0.078%)

since

2025/06/30

13.

Dimensional Fund Advisors, Inc.

(0.0715%)

since

2025/06/30

14.

Morgan Stanley - Brokerage Accounts

(0.0714%)

since

2025/06/30

15.

Geode Capital Management, LLC

(0.0668%)

since

2025/06/30

16.

Fidelity Nasdaq Composite Index

(0.0668%)

since

2025/07/31

17.

abrdn Healthcare Opportunities

(0.0536%)

since

2025/07/31

18.

Susquehanna International Group, LLP

(0.046%)

since

2025/06/30

19.

Change Path, LLC

(0.0458%)

since

2025/06/30

20.

Barclays PLC

(0.0372%)

since

2025/06/30

21.

Mariner Wealth Advisors LLC

(0.0352%)

since

2025/06/30

22.

Connor Clark & Lunn Inv Mgmt Ltd

(0.034%)

since

2025/06/30

23.

Dimensional Emerg Mkt Trgtd Val USD Acc

(0.0309%)

since

2025/07/31

24.

HRT FINANCIAL LLC

(0.0307%)

since

2025/06/30

25.

DFA Emerging Markets Social Core Port

(0.0232%)

since

2025/07/31

26.

DFA Emerging Markets Core Equity 2 I

(0.0199%)

since

2025/07/31

27.

DFA Em Mkts Sustnby Cor 1 Instl

(0.0114%)

since

2025/07/31

28.

ActivePassive International Equity ETF

(0.0099%)

since

2025/08/29

29.

Blackstone Alternative Multi-Strategy I

(0.0098%)

since

2024/12/31

30.

Dimensional World Equity GBP Acc

(0.0073%)

since

2025/07/31

31.

DFA World ex US Core Equity Instl

(0.0055%)

since

2025/07/31

32.

Avantis Emerging Markets Eq ETF USD Acc

(0.0019%)

since

2025/08/29

33.

Dimensional World Allc 60/40 GBP Acc

(0.0018%)

since

2025/07/31

34.

Dimensional EM Cor Eq LC ESG Sc USD A

(0.0017%)

since

2025/07/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2026-03-31

EPS Estimate

-0.13

Latest Release

Date

2025-09-30

EPS Actual

-0.07

EPS Estimate

-0.04

EPS Difference

-0.03

Surprise Percent

-75%

Investing Fit Scorecard

(Last Updated 2025-06-30)

Deep Value
Potential Value Candidate(4)
Defensive
Moderately Defensive(5)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(3.8)
GARP
Not Attractive for GARP(2)
Growth
Weak Growth Prospect(0.5)
Momentum
No Momentum(2)
Net Net
Not Undervalued (Net-Net)(3)
Quality
Low Quality Business(2.5)
Value
Fair Value(6)

Income Statement

(Last Updated 2025-06-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-06-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-06-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.